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Chemoradiotherapy using cisp1atinum (CDDP) as the X-ray intensifier was performed on patients 
with urothelia1 carcinoma. Ten 1esions in 9 patients， 6 patients with postoperative re1apse and 3 who 
received the therapy as a palliative treatment for progressive carcinoma， were eva1uated. Four of the 
patients with postoperative re1apse had undergone adjuvant chemotherapy. On the day of the 
treatment， the 9 patients were given continuous intravenous infusion ofCDDP at the dose 1evel of 5ー12
mg/day prior to externa1 irradiation at 50-66 Gy. The response to the therapy was categorized as 
comp1ete response in 5 patients， partia1 response in 4， and no change in 1. The response rate was 
90%， indicating achievement of a good 10ca1 control. Pain re1ief and improvement of hydronephrosis 
were a1so observed in patients who underwent the therapy for treatment ofprogressive carcinoma. All 
adverse reactions were mi1d in intensity. These resu1ts suggest that the chemoradiotherapy is usefu1 
for both patient groups， those who have a postoperative re1apse and those who undergo the therapy as a 
palliative treatment for progressive carcinoma 
(Acta Urol. Jpn. 49: 311-315， 2003) 


















Tab1e l. Patient characteristics 
Patient characteristics 
No.ofpatients 9 
Median age (range) 67 (59-77) 











Prior CISCA 3 
Disease si te 
Lymph node 7 
Lung 
Bone (evaluable) 2 
Primary site 3 
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D:ドキシフルリジン， C カフェイン， CR: complete response， PR: partial response， 
NC 
NED : no evidence of disease冒
5 mgX25 2 GyX25 
NC: no change， 
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いた.術後化学療法として M-V AC (methotrexate， 



















た部位に関しては CR5例， PR 4例， NC 1例で奏
効率は90%であった.術後の再発転移症例(症例 1-
6)に関しては CR4例， PR 3例と全症例で奏効し
た.また palliati切な目的で施行した 3症例(症例






Table 3. Response according to disease site 
Disease site CR PR NC 
Lymph node (n=7) 3 3 
Lung (n=l) 
Bone (evaluable) (n=2) 2 
Primary site (n=3) 2 
Fig. 1. Computed tomography revealed para-
aortic Iymph node recurrence. 
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Fig. 3. Chest computed tomography revealed 
lung metastasis in the ventral segment 
of upper lobe (S3) and mass adjacent 
to the aorta. 
Fig. 4. The mass adjacent to the aorta was 



























































寒野，ほか :CDDP併用放射線尿路上皮癌 315 
行性の症例で本治療法は有用であると考えられた.
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